Use of Pharmacokinetic Data Below Lower Limit of Quantitation Values
暂无分享,去创建一个
[1] Mats O. Karlsson,et al. Handling Data Below the Limit of Quantification in Mixed Effect Models , 2009, The AAPS Journal.
[2] Mats O. Karlsson,et al. Likelihood based approaches to handling data below the quantification limit using NONMEM VI , 2008, Journal of Pharmacokinetics and Pharmacodynamics.
[3] Vinod P. Shah,et al. Workshop/conference report—Quantitative bioanalytical methods validation and implementation: Best practices for chromatographic and ligand binding assays , 2007, The AAPS Journal.
[4] Courtney V. Fletcher,et al. Impact of censoring data below an arbitrary quantification limit on structural model misspecification , 2008, Journal of Pharmacokinetics and Pharmacodynamics.
[5] R. Straubinger,et al. Ultra-sensitive quantification of corticosteroids in plasma samples using selective solid-phase extraction and reversed-phase capillary high-performance liquid chromatography/tandem mass spectrometry. , 2007, Analytical chemistry.
[6] Mats O. Karlsson,et al. Impact of Omission or Replacement of Data Below the Limit of Quantification on Parameter Estimates in a Two-Compartment Model , 2002, Pharmaceutical Research.
[7] Stuart L. Beal,et al. Ways to Fit a PK Model with Some Data Below the Quantification Limit , 2001, Journal of Pharmacokinetics and Pharmacodynamics.
[8] C. Gerbeau,et al. Evaluation of Pharmacokinetic Studies: Is It Useful to Take into Account Concentrations Below the Limit of Quantification? , 1996, Pharmaceutical Research.
[9] A. B. J. Nix,et al. Assay detection limits: concept, definition, and estimation , 2004, European Journal of Clinical Pharmacology.
[10] William J Jusko,et al. Diversity of mechanism-based pharmacodynamic models. , 2003, Drug metabolism and disposition: the biological fate of chemicals.
[11] A. Chow,et al. Single‐Dose Pharmacokinetics and Pharmacodynamics of RWJ 67657, a Specific p38 Mitogen‐Activated Protein Kinase Inhibitor: A First‐in‐Human Study , 2003, Journal of clinical pharmacology.
[12] W. Jusko,et al. Modeling of dose–response–time data: four examples of estimating the turnover parameters and generating kinetic functions from response profiles , 2000, Biopharmaceutics & drug disposition.
[13] N. Pyszczynski,et al. Fifteen years of operation of a high-performance liquid chromatographic assay for prednisolone, cortisol and prednisone in plasma. , 1994, Journal of chromatography. B, Biomedical applications.
[14] W J Jusko,et al. Pharmacokinetics and pharmacodynamic modeling of direct suppression effects of methylprednisolone on serum cortisol and blood histamine in human subjects , 1989, Clinical pharmacology and therapeutics.